Diabetes

Oral GLP-1 therapy is quickly reshaping how we treat type 2 diabetes, especially for patients who hesitate at the thought of injections. For years, glucagon-like peptide-1 receptor agonists were only available as injectables such as semaglutide and dulaglutide. However, the introduction of semaglutide tablets and the development of higher-dose oral …

GLP-1 receptor agonists have transformed type 2 diabetes care, improving glycemic control, supporting weight loss, and reducing cardiovascular risk. However, disparities in GLP-1 use and access are becoming harder to ignore. Why do some patients gain access quickly while others face barriers at every step? Data suggest that prescribing patterns …

GLP-1 receptor agonists have transformed type 2 diabetes care. Yet for many patients, gastrointestinal side effects from GLP-1 therapy, such as nausea, vomiting, and constipation, can threaten long-term adherence. Have you ever had a patient achieve an impressive A1C reduction but consider stopping therapy because of persistent nausea? You are …

As more patients succeed on GLP-1 therapy, conversations about tapering these medications are becoming increasingly common in metabolic care. When patients reach meaningful goals in weight reduction, A1C improvement, or cardiometabolic risk, clinicians naturally begin asking what comes next. Is it safe to stop treatment? More importantly, can progress be …

Patients taking GLP-1 receptor agonists often describe a surprising change: the “volume” of food thoughts seems to turn down. This experience, often described as a reduction in food noise with GLP-1 therapy, reflects measurable neuroendocrine shifts in appetite regulation and reward signaling. For clinicians, understanding and explaining this phenomenon is …

For years, GLP-1 receptor agonists have been associated with older adults who already have type 2 diabetes or established cardiovascular disease. However, metabolic dysfunction does not suddenly appear at age 60. In fact, obesity, insulin resistance, and prediabetes often begin decades earlier. That is why conversations around GLP-1 therapy in …

A patient’s A1C can look acceptable on paper while everything else is quietly heading in the wrong direction. Cardiovascular risk is rising, kidney function is slipping, and the patient keeps missing follow-up visits because of cost, transportation, or work constraints. Most clinicians have seen this scenario play out, even when …

A missed diagnosis, a delayed follow-up, or a rushed primary care visit can quietly shape the course of diabetes for years. For many patients, especially those outside specialty clinics, these small gaps add up. The challenge is not a lack of clinical knowledge, but a lack of timely support where …

GLP-1 receptor agonists have changed diabetes care faster than almost any therapy in recent history. In many ways, one medication now touches glucose control, weight loss, cardiovascular risk, and even liver health. However, while outcomes have evolved, the typical clinic visit has stayed the same. As a result, clinicians often …

A patient is scheduled for surgery tomorrow morning. During medication reconciliation, you notice they took their weekly semaglutide dose two days ago. They feel fine, but anesthesia is concerned about aspiration risk. Meanwhile, glucose levels are creeping up. Do you hold the medication, continue it, or change course entirely? Situations …